Unveiling Fabtech Technologies IPO: A Deep Dive for Potential Investors
Exploring the opportunity with Fabtech Technologies, a leader in biopharma engineering solutions. Get ready to understand the ins and outs of their upcoming IPO!
The Company at a Glance: Fabtech Technologies
Established in 2018, Fabtech Technologies Ltd stands out as a specialized biopharma engineering firm. They are dedicated to designing and delivering comprehensive turnkey projects, encompassing state-of-the-art cleanroom facilities, advanced modular systems, and bespoke engineering solutions tailored to the biopharmaceutical industry's stringent requirements.
Fabtech Technologies offers end-to-end services, from initial design and detailed engineering to manufacturing, installation, and meticulous project management. Their expertise spans critical areas like cleanroom technology, sophisticated HVAC systems, and essential process equipment. Serving a global clientele, the company ensures every solution adheres to international regulatory standards, making them a reliable partner in the life sciences sector.
Key Service Offerings:
- Integrated Solutions: Guiding clients through the entire bio-pharma manufacturing lifecycle, from strategic direction to market readiness.
- Advanced Water Solutions: Providing a wide array of equipment for purified water, pure steam generation, and water for injections, with capacities ranging from 500 LPH to 50,000 LPH.
- Optimized Air Solutions: Delivering innovative clean air applications that support growth and progress across diverse industries, including life sciences, food & beverage, IT, semiconductor, and aeronautics.
As of July 31, 2025, Fabtech Technologies proudly employed 185 permanent professionals, reflecting their robust operational capabilities.
Fabtech Technologies IPO: Essential Details
Fabtech Technologies is set to launch its mainboard IPO, a book-built issue totaling ₹230.35 crores. This offering consists entirely of a fresh issue of 1.21 crore equity shares.
| Parameter | Detail |
|---|---|
| IPO Date Range | September 29, 2025 – October 1, 2025 |
| Issue Type | Book Building IPO |
| Face Value | ₹10 per share |
| Price Band | ₹181 to ₹191 per share |
| Lot Size | 75 Shares |
| Total Issue Size | 1,20,60,000 shares (₹230.35 Cr) |
| Employee Discount | ₹9.00 per share |
| Listing Exchanges | BSE, NSE |
IPO Timeline: A Quick Overview
Here’s a tentative schedule for the Fabtech Technologies IPO, guiding you through the key dates:
The cut-off time for UPI mandate confirmation is 5 PM on Wednesday, October 1, 2025.
Investment Details: Lot Size and Categories
Investors interested in Fabtech Technologies IPO can bid for a minimum of 75 shares and in multiples thereof. Here’s a breakdown of the minimum and maximum investment amounts across different investor categories:
| Application Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail Individual Investor (Min) | 1 | 75 | 14,325 |
| Retail Individual Investor (Max) | 13 | 975 | 1,86,225 |
| Small HNI (Min) | 14 | 1,050 | 2,00,550 |
| Small HNI (Max) | 69 | 5,175 | 9,88,425 |
| Big HNI (Min) | 70 | 5,250 | 10,02,750 |
IPO Allotment Structure: How Shares are Allocated
The allocation of shares for the Fabtech Technologies IPO will follow this reservation breakdown:
- Qualified Institutional Buyers (QIBs): Not more than 50% of the Net Issue
- Retail Individual Investors (RIIs): Not less than 35% of the Net Issue
- Non-Institutional Investors (NIIs): Not less than 15% of the Net Issue
Employees also have a reservation, with specific bidding limits and potential discounts.
Understanding Fabtech Technologies' Financial Health
Fabtech Technologies has demonstrated impressive financial growth. Between the financial years ending March 31, 2024, and March 31, 2025, the company's revenue surged by 46%, and its Profit After Tax (PAT) increased by a substantial 71%.
| Financial Year Ended | March 31, 2025 (₹ Cr) | March 31, 2024 (₹ Cr) | March 31, 2023 (₹ Cr) |
|---|---|---|---|
| Assets | 426.56 | 269.24 | 213.86 |
| Total Income | 335.94 | 230.39 | 199.91 |
| Profit After Tax (PAT) | 46.45 | 27.22 | 21.73 |
| EBITDA | 47.28 | 40.69 | 34.86 |
| Net Worth | 173.11 | 131.88 | 88.96 |
| Total Borrowing | 54.62 | 9.88 | 34.29 |
Key Performance Metrics: Valuation Insights (as of March 31, 2025)
The market capitalization of Fabtech Technologies IPO is projected at ₹849.04 Cr. Let's look at other crucial performance indicators:
| KPI | Value |
|---|---|
| Return on Equity (ROE) | 30.46% |
| Return on Capital Employed (ROCE) | 24.46% |
| Debt/Equity Ratio | 0.32 |
| Return on Net Worth (RoNW) | 26.83% |
| PAT Margin | 13.83% |
| EBITDA Margin | 14.07% |
| Price to Book Value | 3.57 |
Earnings and Valuation Multiples:
| Metric | Pre-IPO | Post-IPO |
|---|---|---|
| Earnings Per Share (EPS) | ₹14.34 | ₹10.45 |
| Price-to-Earnings (P/E) Ratio (x) | 13.32 | 18.28 |
Note: Pre-IPO EPS is based on pre-issue shareholding and FY25 earnings. Post-IPO EPS is calculated based on post-issue shareholding and annualized FY25 earnings.
Promoters and Their Vision
The driving force behind Fabtech Technologies are its dedicated promoters: Aasif Ahsan Khan, Hemant Mohan Anavkar, Aarif Ahsan Khan, and Manisha Hemant Anavkar. Their collective vision and leadership have been instrumental in shaping the company's trajectory.
Promoter Shareholding:
- Pre-Issue Promoter Holding: 94.61%
- Post-Issue Promoter Holding: The value will be calculated using Equity Dilution (Pre-Issue Shareholding - Post-Issue Shareholding).
Objectives of the IPO: Fueling Future Growth
Fabtech Technologies plans to utilize the net proceeds from this IPO to fund several strategic initiatives aimed at bolstering its growth and market position:
| S.No. | Objective | Expected Amount (₹ Cr) |
|---|---|---|
| 1 | Funding working capital requirements | 1,270.00 |
| 2 | Pursuing inorganic growth initiatives through acquisitions | 300.00 |
| 3 | General Corporate Purposes | (To be determined) |
SWOT Analysis: A Holistic View
A strategic assessment of Fabtech Technologies' internal capabilities and external environment reveals the following:
Strengths:
- Integrated Engineering Solutions: A key provider of turnkey solutions with comprehensive service offerings across the biopharma lifecycle.
- In-house Software Capabilities: Strong technological foundation supporting innovative solutions.
- Diversified Order Book: Projects spread across various geographies, clients, and business verticals, reducing dependency.
- Global Project Execution: Proven track record of executing projects in diverse and challenging environments.
- Efficient Lead Conversion: Strong funneling mechanisms leading to high mandate conversion rates.
- Dosage Form Expertise: Experience in executing projects across all types of dosage forms.
- Experienced Leadership: Backed by seasoned leadership with strong parentage within the Fabtech Group.
Weaknesses:
- Capital Intensive Business: Projects in biopharma engineering often require significant upfront capital investment.
- Dependency on Client Sector Growth: Performance is tied to the growth and investment cycles of the biopharma and healthcare industries.
- Competitive Market: Faces competition from both domestic and international players in the specialized engineering solutions space.
Opportunities:
- Growing Biopharma Sector: Global expansion of pharmaceutical and biotechnology industries drives demand for advanced facilities.
- Technological Advancements: Adoption of new technologies and automation in cleanroom and manufacturing processes.
- Government Initiatives: Supportive policies and incentives for pharmaceutical manufacturing and research globally.
- Inorganic Growth: Opportunity to expand market share and capabilities through strategic acquisitions, as indicated by IPO objectives.
Threats:
- Regulatory Changes: Strict and evolving regulations in the pharmaceutical and healthcare sectors can impact project requirements and timelines.
- Economic Downturns: Global economic slowdowns could lead to reduced capital expenditure by clients.
- Supply Chain Disruptions: Reliance on global supply chains for specialized equipment and components poses risks.
- Intense Competition: High competition may lead to pricing pressures and impact profitability.
Connect with Fabtech Technologies and Registrar
Company Contact Details:
- Address: 715, Janki Centre, Off. Veera Desai Road, Andheri West, Mumbai, Maharashtra, 400053
- Phone: +91 226 159 2900
- Email: cs@fabtechnologies.com
- Website: fabtechnologies.com
IPO Registrar:
The registrar for the Fabtech Technologies IPO is Bigshare Services Pvt.Ltd. They are responsible for managing the IPO application and allotment process.
- Phone: +91-22-6263 8200
- Email: ipo@bigshareonline.com
- Website: ipo.bigshareonline.com/IPO_Status.html
How to Participate in Fabtech Technologies IPO
Applying for the Fabtech Technologies IPO is a straightforward process, typically done online using either UPI or ASBA.
Applying via UPI (Through Broker Platforms):
Many online brokers allow their clients to apply for IPOs using UPI as a payment method. Here’s a general guide:
- Log in to your broker's platform (e.g., their console or back office).
- Navigate to the 'Portfolio' or 'IPO' section.
- Locate the 'Fabtech Technologies IPO' and click on the 'Bid' option.
- Enter your UPI ID, the desired quantity of shares, and the bid price.
- Submit your IPO application.
- Approve the mandate request that appears in your UPI App (like Net Banking or BHIM) within the stipulated time.
Applying via ASBA (Through Your Bank):
ASBA (Application Supported by Blocked Amount) is another popular method available through the net banking portal of your bank account.
- Log in to your bank's internet banking portal.
- Look for the 'IPO' or 'e-ASBA' section.
- Select the 'Fabtech Technologies IPO' and proceed with the application, entering the necessary details.
It is advisable to check with your specific broker or bank for precise application instructions.
Conclusion: A Promising Venture in Biopharma Engineering
Fabtech Technologies Ltd presents an intriguing investment opportunity, leveraging its strong position in the high-growth biopharma engineering sector. With a robust financial performance, a clear vision for growth, and an experienced leadership team, the company appears well-poised for future success.
While the IPO valuation reflects its potential, prospective investors should conduct thorough due diligence, considering both the company's strengths and the broader market dynamics. For those seeking exposure to the specialized industrial solutions space, Fabtech Technologies IPO could indeed be a noteworthy consideration for medium to long-term investment horizons.